Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

An­a­lysts hound Bio­gen with ques­tions over Aduhelm's $56K price point as news of Alzheimer's OK rip­ples through glob­al mar­kets

It’s been near­ly 24 hours since the FDA hand­ed down its con­tro­ver­sial de­ci­sion to ap­prove Bio­gen’s Aduhelm drug for Alzheimer’s dis­ease, and re­ac­tions from around the in­dus­try are pour­ing in as an­a­lysts try to size up the ram­i­fi­ca­tions of Mon­day’s news.

Bio­gen host­ed an in­vestor call Tues­day morn­ing, pro­vid­ing a fo­rum for a num­ber of top­ics that have been top of mind. The call came as the news of Aduhelm’s ap­proval in the US rip­pled through glob­al mar­kets, while $BI­IB stock soared to around $380 apiece (up from $286 on Fri­day), as Bio­gen’s part­ners at Ei­sai seek new ap­provals in Asia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.